Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 18,737 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis
Interventions: VNZ/TEZ/D-IVA, Rosuvastatin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Polycythemia Vera
Interventions: XL019; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 2 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Bevacizumab, Erlotinib, Prednisone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: FB704A, Placebo; Drug
Lead sponsor: Fountain Biopharma Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteer
Interventions: ACHN-975, placebo; Drug
Lead sponsor: Achaogen, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: COVID-19
Interventions: COVID-HIGIV, Placebo (saline); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: TAK-788, Itraconazole, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Interventions: Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 29
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 25 more

Conditions: Major Depressive Disorder
Interventions: (2R,6R)-Hydroxynorketamine hydrochloride, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Choroidal Neovascularization
Interventions: Imatinib Mesylate /Ranibizumab; Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 51 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Myelodysplastic Syndromes
Interventions: sodium stibogluconate; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Neoplasms
Interventions: BI 905677; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Hemophilia A
Interventions: BAX 888; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 5 more

Conditions: Cystic Fibrosis
Interventions: PTI-428, Placebo; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 20
States / cities: Stanford, California • Altamonte Springs, Florida • Gainesville, Florida + 16 more

Conditions: Obesity
Interventions: PF-06882961, Rosuvastatin, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Platelet Aggregation Inhibitors
Interventions: Aspirin; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, progenipoietin, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: MUC1-KLH vaccine/QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumors, Hematologic Malignancies, Hepatic Impairment
Interventions: Carfilzomib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Detroit, Michigan • Durham, North Carolina • Canton, Ohio + 2 more

Conditions: Healthy Volunteers
Interventions: [14C]BMS-986419; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Leukemia, Lymphoma
Interventions: filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, mitoxantrone hydrochloride, pentostatin, fluorescence in situ hybridization, gene rearrangement analysis, polymerase chain reaction, protein expression analysis, flow cytometry, biopsy; Biological · Drug · Genetic + 2 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
Interventions: AZD4144, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Glendale, California • Daytona Beach, Florida • Jacksonville, Florida + 6 more

Search by objective public record fields.

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

A Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

A Study of BAX 888 in Male Adults With Severe Hemophilia A

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Vaccine Therapy in Treating Patients With Breast Cancer

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.